Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Free Research Reports on ACAD, ANTH, BPAX, VHC Issued by the Bedford Report
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY -- (Marketwire) -- 11/26/12 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. The company is on track to release results from their Phase III trial of pimavanserin in patients with Parkinson's disease psychosis later this month.

Find out more about ACADIA Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ACAD

Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) shares of the biopharmaceutical company have fallen nearly 90 percent year-to-date. The company recently announced that that an abstract of the results from the Phase 2b PEARL-SC clinical study has been accepted as a late-breaking poster presentation at the ACR/ARHP 2012 Annual Scientific Meeting.

Find out more about Anthera Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ANTH

Biosante Pharmaceuticals Inc. (NASDAQ: BPAX) shares have fallen nearly 60 percent year-to-date. The company earlier this month announced that it has entered into a definitive merger agreement with ANI Pharmaceuticals, Inc., who had net sales of over $16 million in 2011.

Find out more about Biosante Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/BPAX

VirnetX Holding Corporation (NYSE: VHC) shares surged earlier this month after it was reported that the company was awarded a large settlement. A jury has ordered Apple to pay the company $368 million.

Find out more about VirnetX including full access to the free equity report at: www.BedfordReport.com/VHC

Disclaimer: Equity News Circuit is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, bedfordreport.com has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release.

Contact Information:

Equity News Circuit
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
You are moving to the Cloud. The question is not if, it’s when. Now that your competitors are in the cloud and lapping you, your “when” better hurry up and get here. But saying and doing are two different things. In his session at @DevOpsSummit at 18th Cloud Expo, Robert Reeves...
What does it look like when you have access to cloud infrastructure and platform under the same roof? Let’s talk about the different layers of Technology as a Service: who cares, what runs where, and how does it all fit together. In his session at 18th Cloud Expo, Phil Jackson,...
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract busines...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed...
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE